BioVie Inc.

BioVie Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drug therapies. The company focuses on addressing chronic debilitating conditions, particularly neurological and neurodegenerative disorders, and advanced liver disease. Headquartered in Carson City, Nevada, BioVie aims to enhance patient outcomes by targeting underlying biological drivers of these diseases.

BioVie's pipeline features two primary drug candidates: Bezisterim (NE3107) and BIV201. Bezisterim is an orally bioavailable, blood-brain barrier–permeable modulator of inflammation and an insulin-sensitizing agent, currently undergoing Phase III clinical trials for mild to moderate Alzheimer's disease, Phase 2 trials for Parkinson's disease, and Phase 2 trials for neurological symptoms associated with long COVID. BIV201 is a continuous infusion terlipressin therapy being developed for the treatment of ascites due to chronic liver cirrhosis, which has received FDA Orphan Drug designation and Fast Track status.

Under the leadership of President and CEO Cuong Viet Do, BioVie has recently achieved several clinical milestones, including the completion of enrollment in its Phase 2 ADDRESS-LC trial for Bezisterim in Long COVID and the completion of patient visits in the Phase 2 SUNRISE-PD trial for Parkinson's disease in May 2026. The company also expanded its governance with new board appointments and the formation of a Corporate Advisory Board in 2025. BioVie operates as a publicly traded entity with its shares listed on NASDAQ under the ticker symbol BIVI.